<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190730044383N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-02-18</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of efficacy of different nerve block with ultrasonic guide for postoperative pediatric pain management</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of efficacy of transversus abdominis plane block and iliohypogastric/ilioinguinal ultrasonic block for postoperative pain management in pediatric patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-09-18</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>50</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/41189</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization will be a layer randomization such that depending on patient ID , if the ID is an even number, ultrasound guidance TAP block will be conducted for him/her and if it is odds number, the ultrasound guidance IIN / IHN block will be done, Blinding description: The head of the operating room of the Tabriz Pediatric Hospital will be aware of this. During surgery and after recovery, the examiner will examine the patient and record the relevant criteria for the patient without knowing which treatment method is selected. The statistical analyzer is also unaware of the block method and therefore will be a triple blind study.The surgery was the same in both groups but the analgesic method differed in both groups. depending on patient ID , if the ID is an even number, ultrasound guidance TAP block will be conducted for him/her and if it is odds number, the ultrasound guidance IIN / IHN blockwill be done.
And since the anesthesiologist will proceed with the procedure according to the file number, so he or she will not be aware of the child's grouping, so the parents of the child are also unaware of the type of block.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Comparison of the efficacy of abdominal transverse muscle block block with ileohypogastric / ileoengyngal block.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: in this group ultrasound probe is placed transversely in midaxillary line,  between iliac crest and inferior rib margins. After ultrasonographic view of abdominal wall layer is obtained , Needle guge of 20 or 22 (according to the child's age) is inserted  medial to the lateral plane and after reaching the needle tip to the fascia between the IO and TA muscles 0.4ml / kg of 0.25% bupivacaine solution (ie 1mg). / kg) will be injected. In case of bilateral inguinal hernia repair (or surgical incision beyond the midline of the body), in each case, the above-mentioned area blocks will be bilateral. In all of the above, the dose of topical anesthesia drugs should not exceed toxic dosage (2mg / kg bupivacaine). Intervention 2: Control group:  In this group  the ultrasound probe is placed  transversely in center of imaginary line between  anterior superior iliac spine and navel and the lateral end of the probe adheres to the anterior superior iliac spine  Needle score of 20 or 22 (according to child's age) is in-plane medially lateral to body and after needle tip reached to fascia between IO and TA muscles 0.2ml / kg of 0.25% bupivacaine solution (ie 0.5 mg / kg) will be injected in the vicinity of the above nerves and a "Kayak" view or mark will be obtained.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is No more information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Behzad Sharbiani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Golghast St., Azadi St ،Tabriz</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166614756</zip>
        <telephone>+98 41 3336 3176</telephone>
        <email>sharabiani48@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Arefeh Khanghlan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Golghast St., Azadi St ،Tabriz</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166614756</zip>
        <telephone>+98 41 3336 3176</telephone>
        <email>Arefe6876@gmil.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Children aged 6-12 years old
Children with ASA Class I and II requiring inguinal hernia repair</inclusion_criteria>
      <agemin>6 years</agemin>
      <agemax>12 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Parental dissatisfaction with performing regional block
Allergy to local anesthesia will be</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>ندارد</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>ندارد</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: in this group ultrasound probe is placed transversely in midaxillary line,  between iliac crest and inferior rib margins. After ultrasonographic view of abdominal wall layer is obtained , Needle guge of 20 or 22 (according to the child's age) is inserted  medial to the lateral plane and after reaching the needle tip to the fascia between the IO and TA muscles 0.4ml / kg of 0.25% bupivacaine solution (ie 1mg). / kg) will be injected. In case of bilateral inguinal hernia repair (or surgical incision beyond the midline of the body), in each case, the above-mentioned area blocks will be bilateral. In all of the above, the dose of topical anesthesia drugs should not exceed toxic dosage (2mg / kg bupivacaine)</i_keyword>
      <i_keyword>Control group:  In this group  the ultrasound probe is placed  transversely in center of imaginary line between  anterior superior iliac spine and navel and the lateral end of the probe adheres to the anterior superior iliac spine  Needle score of 20 or 22 (according to child's age) is in-plane medially lateral to body and after needle tip reached to fascia between IO and TA muscles 0.2ml / kg of 0.25% bupivacaine solution (ie 0.5 mg / kg) will be injected in the vicinity of the above nerves and a "Kayak" view or mark will be obtained.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The amount of pain. Timepoint: 6 to 12 months after surgery. Method of measurement: visual analogue scale.</prim_outcome>
      <prim_outcome>The amount of used analgesic drug. Timepoint: recovery period. Method of measurement: Questionnaire.</prim_outcome>
      <prim_outcome>The time it takes to do the block. Timepoint: during the procedure. Method of measurement: Questionnaire.</prim_outcome>
      <prim_outcome>The time that patient needs the first analgesic drug. Timepoint: during recovery. Method of measurement: Questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-07-30</approval_date>
        <contact_name>Ethics Committee of Tabriz Medical School</contact_name>
        <contact_address>Imam Reza Hospital, Golghast street, Azadi street, Tabriz Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
